How does PT-141 work mechanistically?

PT-141 is a selective agonist of the melanocortin-4 receptor (MC4R), which is expressed in the hypothalamus and other brain regions involved in sexual response. Activation of MC4R increases sexual arousal and desire through central (brain) mechanisms, not peripheral vascular effects. This is why it differs fundamentally from phosphodiesterase inhibitors like sildenafil (Viagra).

What is the clinical evidence for PT-141?

PT-141 completed Phase 3 trials (the DESIRE studies) in women with HSDD and was approved by the FDA in 2019. The primary endpoint was increase in satisfying sexual events per month. Clinical trial data showed statistically significant improvements in sexual desire and arousal compared to placebo in premenopausal women.

How is PT-141 administered?

The FDA-approved form of PT-141 (Vyleesi) is a subcutaneous injection used on demand according to the prescribing information. Nasal spray formulations have been studied in research, but the approved medicine is injectable. Online nasal-spray marketing claims should be treated with caution. This page does not provide dosing guidance.

Is PT-141 different from Viagra (sildenafil)?

Yes. The mechanisms differ. Viagra is a phosphodiesterase-5 inhibitor that increases blood flow to genital tissue. PT-141 is a melanocortin receptor agonist that works on the central nervous system to increase arousal and desire. They address different physiological systems. Combined-use evidence is limited.

What are the known side effects of PT-141?

Common side effects in clinical trials included nausea (25-40% in some dosing arms), facial flushing, and headache. More serious but rare side effects include blood pressure changes and darkening of the skin (due to melanocortin's effect on melanin production). Individual tolerability varies and lower doses may reduce side effect burden.

Shop by goal

Metabolic Signalling

GH-Axis Research

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Popular compounds

Research resources

Certificates of Analysis

PT-141 (Bremelanotide): a research guide to the melanocortin agonist for sexual arousal

Q: What is PT-141 (bremelanotide)?

PT-141 is a 7-amino-acid melanocortin-4 receptor (MC4R) agonist, FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works through a different mechanism than Viagra-class drugs: rather than increasing blood flow, it acts on the central nervous system to increase sexual arousal and desire.

In short: PT-141 (bremelanotide) is a 7-amino-acid selective melanocortin-4 receptor (MC4R) agonist. The FDA approved it as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally, unlike PDE5 inhibitors that mainly change genital blood flow. Research-grade material is a separate category. Research use only.

Key facts

Heptapeptide MC4R agonist; related to, but not the same as, melanotan-2.

Licensed medicine: Vyleesi (2019) for premenopausal HSDD; DESIRE Phase 3 programme.

Mechanism is central (brain arousal/desire pathways), not primarily vascular.

Approved product is subcutaneous injection; “nasal spray” retail claims need caution.

New-U framing: research education and RUO reagents, not medical advice or dosing guidance.

What is PT-141 (bremelanotide)?

PT-141 is the research and generic name for bremelanotide, a synthetic heptapeptide. The FDA approved it in 2019 as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD). Its mechanism differs from phosphodiesterase inhibitors such as Viagra or Cialis.

PT-141 is related structurally to melanotan-2, another melanocortin agonist, but with different selectivity and clinical history. Melanotan-2 was studied for tanning and erectile-function models. PT-141 was developed toward the arousal and desire pathway that led to the HSDD indication.

Research context: PT-141 development involved Palatin Technologies, and the compound sat in clinical development for over a decade before the FDA approval of Vyleesi in 2019. The DESIRE (female sexual desire) clinical trial programme drove regulatory approval.

Mechanism: melanocortin receptor signalling

PT-141 works as a selective agonist of the melanocortin-4 receptor (MC4R) . MC4R is a G-protein-coupled receptor in hypothalamic and related brain regions tied to sexual motivation and arousal. This is a central nervous system mechanism. It does not primarily alter genital blood flow, which is why it differs from phosphodiesterase inhibitors.

The melanocortin pathway is multifunctional. It is studied in appetite, energy homeostasis, immune signalling and sexual behaviour. MC4R activation in hypothalamic nuclei increases sexual motivation in animal models. Human trials reported changes in subjective arousal and desire under study conditions.

Greater MC4R selectivity reduces some off-target melanocortin effects compared with broader agonists. Skin darkening is still a documented adverse event in a subset of trial participants.

Clinical evidence: the DESIRE trials

PT-141’s path to approval was the DESIRE trial programme : Phase 3 randomised controlled trials in premenopausal women with HSDD. The primary endpoint was an increase in satisfying sexual events per month, a patient-reported outcome rather than a mechanistic surrogate.

Trial design snapshot: Participants were randomised to placebo or PT-141 across studied dose arms. Trials reported statistically significant improvements versus placebo on desire, arousal and satisfying sexual events. Effect sizes were modest but directionally consistent across the programme.

Nausea was common in the trials and was dose-related. Blood pressure elevations were also observed and required monitoring in the clinical programme. The trials enrolled hundreds of participants over several months and formed the evidence base for the HSDD indication in women.

Vyleesi’s FDA approval is restricted to premenopausal women with HSDD. Use outside that labelled population is outside the approval and has a different evidence base. This page does not provide medical advice or dosing guidance.

PT-141 vs Viagra, Cialis, and sildenafil class drugs

The comparison is mechanistic, not clinical:

Phosphodiesterase inhibitors (PDE5i) - Viagra (sildenafil), Cialis (tadalafil), Levitra (vardenafil) - work peripherally by increasing cGMP in vascular smooth muscle, increasing blood flow to erectile tissue. They are approved for erectile dysfunction in men and some women. The dose is taken minutes to hours before sexual activity.

PT-141 (melanocortin agonist) - works centrally on the brain to increase arousal and sexual desire, independently of vascular mechanisms. It is approved for desire disorder in women, not erectile dysfunction per se. It is injected subcutaneously 45 minutes before anticipated sexual activity.

A key difference: PDE5 inhibitors improve the mechanics of sexual response (blood flow, erection); PT-141 enhances the motivation and desire for sexual activity. They address different physiological systems. Combined use is theoretically possible but clinical data is sparse. In clinical practice, some prescribers have explored combination therapy for patients who respond partially to one agent alone.

Administration: nasal spray vs injection

The FDA-approved form of PT-141 (Vyleesi) is a subcutaneous injection, not a nasal spray. Labelled use follows the medicine’s prescribing information. This article does not repeat a dosing protocol.

Nasal spray formulations of PT-141 and related melanocortin agonists have been studied in research settings. Some trials or compounded preparations may use intranasal routes. Online marketing claims about “PT-141 nasal spray” should be viewed with caution. Those products are typically not FDA-approved, and purity, stability and strength claims are often unverified.

Formulation red flag: If you encounter PT-141 marketed as a nasal spray at a non-medical e-commerce site, the product is either research-stage compound (unregulated) or misrepresented. The approved pharmaceutical product is injectable only.

Side effects and tolerability

PT-141's adverse event profile from clinical trials:

Nausea (25-40% depending on dose) - the most common and often dose-limiting side effect. Taking food or antiemetics before dosing may help.

Facial flushing - common, usually transient.

Headache - reported in trials, incidence varied by arm.

Darkening of the skin - due to melanocortin's effect on melanin production. This is reversible but can be cosmetically concerning; it occurs more in darker-skinned individuals and at higher doses.

Blood pressure changes - increases in systolic and diastolic BP were observed; monitoring is advised especially in hypertensive individuals.

Contraindications and cautions include uncontrolled hypertension, coronary artery disease, and concurrent use of strong CYP3A4 inhibitors. Pregnancy is a clear contraindication (the indication is premenopausal HSDD, but contraception is required). Renal and hepatic impairment may affect tolerability.

PT-141 in research context

From a research perspective, PT-141 is valuable as a tool to study melanocortin signalling in sexual behaviour and motivation. The MC4R is a well-validated target in rodent models of sexual function, and PT-141's approval provides clinical confirmation that central melanocortin activation can modulate human sexual desire in women.

Ongoing research areas include:

Combination strategies - PT-141 + PDE5i for synergistic effect in mixed presentations.

Postmenopausal applications - the DESIRE trials did not include postmenopausal women; efficacy and safety in that population remain unknown.

Male sexual dysfunction - despite the initial melanotan-2 development in that context, PT-141's mechanism may differ and clinical evidence in men is absent.

Formulation optimisation - nasal spray and oral variants have been studied to improve convenience, though efficacy vs. the approved injection remains to be established.

Frequently Asked Questions

Is PT-141 the same as melanotan-2? No. Both are melanocortin agonists, but PT-141 (bremelanotide) is a 7-amino-acid peptide optimised for sexual desire in women, while melanotan-2 is a larger, less selective compound originally studied for tanning and erectile dysfunction. PT-141 has FDA approval; melanotan-2 does not.

Can I use PT-141 if I am on blood pressure medication? PT-141 itself can raise blood pressure. Use with antihypertensive drugs requires medical supervision and monitoring. Do not self-prescribe.

How quickly does PT-141 work? In the licensed injectable setting, onset is described in the prescribing information as on-demand use ahead of anticipated sexual activity. Duration is measured in hours, not days. Follow the medicine label; this page is not dosing advice.

Can PT-141 be used daily? Vyleesi is labelled for on-demand use, not as a daily maintenance therapy. Frequency limits are defined in the prescribing information. Research reagents are not medicines.

Does PT-141 work better than Viagra for women? The clinical indications are different - Viagra addresses erectile dysfunction mechanisms in men and some women; PT-141 addresses desire/arousal disorder specifically. "Better" depends on the underlying physiology. Some women may benefit from PT-141 if their primary concern is desire; others may respond better to vascular agents if flow is the limiting factor.

Primary sources & further reading

U.S. FDA - Vyleesi (bremelanotide) approval announcement

Palatin Technologies - Clinical development history

PubMed - Bremelanotide / PT-141 literature

NIH - Melanocortin receptor signalling in sexual behaviour

New England Journal of Medicine - Archive: HSDD clinical trial evidence

External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way. This article is general educational information, not medical advice.

From the Lab - Peptides on LinkedIn & Facebook

Research Compounds & Peptides

New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy PT-141 from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research

Support

Ways to Pay

Shop by goal

Muscle & IGF Research

Tissue and Cellular Models

Regenerative Research

Cellular Senescence Research

Cognitive Research

Multi-Compound Blends

Shop by compound

CJC-1295 (without DAC)

Shop by region

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.